A Case of inflammatory nonscarring alopecia associated with the tyrosine kinase inhibitor nilotinib

JAMA Dermatology

Volumn 149, Issue 3, 2013, Pages 330-332

  Hansen, Timothy ^a   Little, Anthony J ^b   Miller, Jeffrey J ^a   Ioffreda, Michael D ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NILOTINIB;

ADULT; ALOPECIA; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DERMATITIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSKERATOSIS; ERYTHEMA; FEMALE; HAIR FOLLICLE; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; NONHUMAN; PAPULE; PRIORITY JOURNAL; PUNCH BIOPSY; SKIN BIOPSY; SKIN EXAMINATION;

ADULT; ALOPECIA; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INFLAMMATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 84875390011     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.1375     Document Type: Article

References (17)

1. Hepper DM, Wu P, Anadkat MJ. Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol. 2011;64(5): 996-998.
2. Graves JE, Jones BF, Lind AC, Heffernan MP. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J Am Acad Dermatol. 2006;55(2):349-353.
3. Robert C, Soria JC, Spatz A, et al. Cutaneous sideeffects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491-500.
4. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol. 2008;58(4):545-570.
5. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008;144(7):886-892.
6. Tasigna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.
7. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542-2551.
8. Manley PW, Drueckes P, Fendrich G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804 (3):445-453.
9. McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther. 2011;24(4):396-400.
10. Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008;16(6):557-566.
11. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045-1051.
12. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12(4):426-437.
13. Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reactionwith sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008;47(2):176-186.
14. Saito Y, Haendeler J, Hojo Y, Yamamoto K, Berk BC. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol. 2001;21(19):6387-6394.
15. King LE Jr, Gates RE, Stoscheck CM, Nanney LB. The EGF/TGF alpha receptor in skin. J Invest Dermatol. 1990;94(6)(suppl):164S-170S.
16. Tomita Y, Akiyama M, Shimizu H. PDGF isoforms induce and maintain anagen phase of murine hair follicles. J Dermatol Sci. 2006;43(2):105-115.
17. Hansen LA, Alexander N, Hogan ME, et al. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am J Pathol. 1997;150(6):1959-1975.